

Serial No. 10/820,121  
 Amdt. dated December 12, 2005  
 Reply to Office Action of August 17, 2005


Page 2 of 7

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Currently Amended) A pharmaceutical preparation for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections, or viral diseases, comprising one or more salts Salts of guanidine derivatives corresponding to the formula



wherein

X represents ~~a valence bond, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-NH-NH- or -CH=N-NH-~~,

R represents a linear or branched C<sub>1</sub>-C<sub>30</sub> alkyl, C<sub>3</sub>-C<sub>20</sub> cycloalkyl, ~~adamantyl, norbornyl, or tricyclodecyl, benzyl, furyl, pyridyl, anthracyl, naphthyl, phenanthryl, perinaphthyl or quinuclidinyl~~ residue, which can be substituted by one or more hydroxyl groups, C<sub>1</sub>-C<sub>4</sub> alkoxy groups, C<sub>1</sub>-C<sub>4</sub> alkyl groups and/or one or more halogen atoms or one or more amino groups, and

Z represents O-CO-Y, O-S(O)<sub>2</sub>-Y, or O-P(O)(OH)-Y, wherein Y represents a linear or branched C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, benzyl, furyl or pyridyl residue, which can be substituted by one or more hydroxyl groups, carboxylic acid groups, C<sub>1</sub>-C<sub>4</sub> alkoxy groups, C<sub>1</sub>-C<sub>4</sub> alkyl groups and/or one or more halogen atoms or one or more amino groups.

2. (Currently Amended) The preparation Salt according to Claim 1, wherein Z represents O-CO-Y.

Serial No. 10/820,121  
Amdt. dated December 12, 2005  
Reply to Office Action of August 17, 2005

Page 3 of 7

3. (Currently Amended) The preparation Salt according to Claim 1,2, wherein R represents a pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, cyclododecyl, tricyclo[5,2,1,5,2,1,0<sup>2,6</sup>]-decyl, or bicyclo[2,2,1,2,2,1]-cyclohexyl or tolyl-residue.
4. (Currently Amended) The preparation Salt according to Claim 1,2, wherein R represents a decyl residue.
5. (Currently Amended) The preparation Salt according to Claim 1,2, wherein Y is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, hydroxyethyl or 2-hydroxy-2,3-dicarboxylic acid propyl.
6. (Cancelled)
7. (Currently Amended) The preparation Salt according to Claim 5,2, wherein R represents a decyl residue; ~~X represents  $\text{CH}_2\text{NHNH}$  or  $\text{CH=N NH}$ ; and Y is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, hydroxyethyl, or 2-hydroxy-2,3-dicarboxylic acid propyl.~~
8. (Currently Amended) The preparation Salt according to Claim 1,2, said salt being undecylideneaminoguanidine acetate or undecylideneaminoguanidine lactate.
9. (Currently Amended) The preparation Salt according to Claim 1,2, said salt being undecylideneaminoguanidine oenanthate or undecylideneaminoguanidine pelargonate.
10. (Currently Amended) The preparation Salt according to Claim 1,2, said salt being undecylideneaminoguanidine decanoate.
11. (Currently Amended) The preparation Salt according to Claim 1,2, said salt being undecylideneaminoguanidine hexanoate.
12. (Currently Amended) The preparation Salt according to Claim 1, wherein Z is  $\text{O-S(O)}_2$ -Y (sulfonic acid group), or  $\text{O-P(O)(OH)-Y}$  (phosphericphosphonic acid group).


Serial No. 10/820,121  
 Amdt. dated December 12, 2005  
 Reply to Office Action of August 17, 2005

Page 4 of 7

13. (Cancelled)

14. (Currently Amended) The preparation ~~Pharmaceutical preparation~~ according to Claim 1-13, further comprising a common pharmaceutically acceptable additives and/or excipients.

15. (Currently Amended) Method for the preparation of a pharmaceutical preparation for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections, or viral diseases, comprising combining one or more salts of guanidine derivatives corresponding to the formula



wherein

X represents -CH<sub>2</sub>-NH-NH- or -CH=N-NH-

R represents a linear or branched C<sub>1</sub>-C<sub>30</sub> alkyl, C<sub>3</sub>-C<sub>20</sub> cycloalkyl, or tricyclodecyl residue, which can be substituted by one or more hydroxyl groups, C<sub>1</sub>-C<sub>4</sub> alkoxy groups, C<sub>1</sub>-C<sub>4</sub> alkyl groups and/or one or more halogen atoms or one or more amino groups, and

Z represents O-CO-Y, O-S(O)<sub>2</sub>-Y, or O-P(O)(OH)-Y, wherein Y represents a linear or branched C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, benzyl, furyl or pyridyl residue, which can be substituted by one or more hydroxyl groups, carboxylic acid groups, C<sub>1</sub>-C<sub>4</sub> alkoxy groups, C<sub>1</sub>-C<sub>4</sub> alkyl groups and/or one or more halogen atoms or one or more amino groups,  
processing a salt according to Claim 2 with common a pharmaceutically acceptable additives and/or excipients to produce an administrable form.

16. (Currently Amended) Method according to Claim 15, comprising: wherein the salt is processed to an administrable form by providing approximately equimolar amounts of the corresponding base and acid, and combining the base and acid with the pharmaceutically acceptable processing with common additives and/or excipients.

Serial No. 10/820,121  
Amdt. dated December 12, 2005  
Reply to Office Action of August 17, 2005

Page 5 of 7

17. (Cancelled)

18. (Currently Amended) Method for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections, or viral diseases comprising administering to a patient a pharmaceutically effective amount of the pharmaceutical preparation of claim 1 salt of ~~Claim 2~~.